Information Provided By: 
Fly News Breaks for July 18, 2017
PBYI
Jul 18, 2017 | 08:10 EDT
Stifel analyst Thomas Shrader raised his price target on Puma after the company announced that its neratinib drug for breast cancer had been approved. The analyst says the company now probably has to decide whether to build a sales force or sell itself. He thinks that the drug's "surprisingly broad label" has made the company more attractive to potential acquirers. Shrader keeps a Buy rating on the shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
